Key Points for Decision Makers {#FPar1}
==============================

Patient satisfaction with new treatments is critical, and effective convenient treatments that integrate well into patients' lives contribute toward this. Overall patient satisfaction was favorable for the belimumab autoinjector compared with intravenous administration of belimumab.Patients considered the belimumab autoinjector to be more convenient than intravenous belimumab because of the shorter administration time, decreased travel time, portability, and reduced/no pain.Regardless of administration route, many patients reported improvements in activities of daily living with belimumab. Furthermore, compared with intravenous administration, 59% of employed patients stated that the autoinjector improved their ability to work and 40% reported that their ability to carry out daily activities improved.

Introduction {#Sec1}
============

Intravenous administration of belimumab 10 mg/kg plus standard of care (SoC) for systemic lupus erythematosus (SLE) is licensed for use in over 60 countries (including countries in Europe, the USA, Canada, and Australia) for the treatment of SLE in adults with active, autoantibody-positive disease \[[@CR1]\]. Administration of intravenous belimumab requires patients to visit a clinic or infusion center every 4 weeks. A study evaluating satisfaction with belimumab and SLE treatment indicated that \>50% of patients receiving intravenous belimumab would prefer to self-administer their treatment at home; this preference was more common among patients who were employed or were students \[[@CR2]\]. Self-administration could potentially save time and reduce costs for both patients and the health service \[[@CR3]\]. However, currently belimumab is only available by intravenous administration in a clinic.

An autoinjector device and prefilled syringe have been developed for subcutaneous administration of belimumab to enable self-administration of treatment. Initial trials of a single dose of subcutaneous belimumab in healthy volunteers, self-administered using the autoinjector or prefilled syringe, demonstrated acceptable pharmacokinetic, tolerability, reliability, usability, and safety profiles \[[@CR4]\]. A subsequent phase II, open-label, single-arm, multi-dose study of subcutaneous belimumab in patients with SLE in real-life conditions (GSK study 200339; NCT02124798) demonstrated that the autoinjector was reliable and well tolerated for home administration \[[@CR5]\]. Patient assessments indicated a good level of usability and safety was consistent with the known safety profile of belimumab. Reported pain on injection was low and decreased with repeated administration as patients gained experience with using the device.

The efficacy and safety of subcutaneous belimumab using a prefilled syringe plus SoC was demonstrated in a 52-week, phase III, randomized, double-blind, placebo-controlled pivotal trial (BLISS-SC) \[[@CR6]\]. Results from this study were consistent with outcomes observed in the phase III BLISS studies among adults treated with intravenous belimumab plus SoC \[[@CR7], [@CR8]\].

Compared with other routes of administration, subcutaneous treatment formulations can have advantages in terms of convenience, ease of use, and the possibility of self-administration \[[@CR3]\]. However, there may also be disadvantages, including anxiety and adverse injection-site reactions \[[@CR3]\]. Evidence comparing patients' perspective of subcutaneous and intravenous routes of administration is lacking \[[@CR3]\]. Herein, we discuss the results from a follow-up of the phase II study that assessed patient experience and satisfaction with the autoinjector and the impact of adding subcutaneous belimumab to SoC.

Patients and Methods {#Sec2}
====================

Objectives {#Sec3}
----------

The primary objectives of this study were to assess patients' experiences using the autoinjector to deliver belimumab, with regard to satisfaction, ease and convenience of use, confidence using the device, and their broader experience with belimumab. Secondary objectives were to explore patient experiences associated with switching to the autoinjector from intravenous or subcutaneous prefilled syringe administration, and patient preferences for administration routes. Exploratory subgroup analyses included investigating changes in symptoms related to duration of belimumab treatment, ability to work, and preference for route of administration.

Study Design and Study Population {#Sec4}
---------------------------------

This cross-sectional study recruited patients who completed the phase II multi-dose usability, tolerability, and safety study of subcutaneous belimumab via autoinjector (GSK Study 200339; NCT02124798) \[[@CR5]\]. The design and inclusion/exclusion criteria of the parent study have been reported previously \[[@CR5]\]: patients receiving intravenous belimumab (*n* = 93) or subcutaneous belimumab using a prefilled syringe (*n* = 2) were eligible to switch to subcutaneous belimumab using an autoinjector device. Following training on use of the autoinjector, patients self-administered weekly doses of belimumab for 8 weeks, 4 with supervision at the clinic (at weeks 1, 2, 4, and 8) and 4 at home (at weeks 3, 5, 6, and 7).

Patients were recruited to this follow-up study by site personnel at their week 8 (NCT02124798) visit or by telephone/in person following this visit.

The present study comprised two parts: a self-administered questionnaire followed by qualitative telephone interviews among a subset of patients who agreed to be contacted. Patients completed the questionnaire online (a paper-based version was provided if requested) within 14 days of their week 8 (NCT02124798) visit. Only data obtained within this time period were included in the primary analyses.

Patients who completed the questionnaire and indicated interest in a follow-up telephone interview were invited to participate in a pre-scheduled one-on-one telephone interview within 21 days of their week 8 (NCT02124798) visit; a sample of 30 patients was the target number of interviews. Patients were remunerated for completing the survey and interview.

Institutional review board approval was obtained at all sites prior to study initiation. Patients provided consent (online) to participate in the online questionnaire and written informed consent prior to paper questionnaire administration and telephone interviews.

Questionnaire and Interview Development and Content {#Sec5}
---------------------------------------------------

The questionnaire and a semi-structured telephone interview guide were developed for this study based on a review of the literature and evaluation of SLE-specific patient-reported outcome instruments \[[@CR2], [@CR9], [@CR10]\]. The questionnaire comprised 43 items, including background information (two items), sociodemographic/clinical characteristics (two items), and the assessment of patients' experience with belimumab (11 items), experience with the autoinjector (nine items; in the Electronic Supplementary Material \[ESM\] 1), experience with intravenous belimumab (seven items), experience with belimumab administered by prefilled syringe (eight items), and impact of delivery method on health-related quality of life (HRQoL; i.e. work/daily activity performance \[four items\]). The majority of questions utilized Likert-scale responses, with patients required to recall experiences with belimumab since the beginning of treatment. The questionnaire responses were used to evaluate changes in symptoms, including the frequency and severity of flares, while using belimumab.

The semi-structured telephone interview guide comprised 24 open-ended questions, with instructions and probes to help the interviewer direct the discussion based on participant responses. This interview guide was designed to gain more detailed information about patients' experience with belimumab, including changes in symptoms (i.e., the frequency and severity of flares), the impact of belimumab treatment on HRQoL, patients' experience with switching administration routes, and preference for administration routes. The following is an example of an open-ended question included in the interview guide (further examples are provided in ESM 2):"Have you experienced any changes in your ability to engage in day-to-day activities since starting Benlysta \[belimumab\]? (use participant's responses to Q8 and Q9 of the questionnaire to help guide the discussion). If so, what changes have you experienced? Probe (if not mentioned): improvement or worsening in the following areas of life: work (e.g., attendance, performance); personal relationships (e.g., family, friendships); leisure (engaging in activities you enjoy); daily living (e.g., grooming, bathing, running errands)."

Questionnaire responses were reviewed prior to the telephone interviews to inform the interviewer and to limit the duplication of questions. Interviews were designed to be completed within approximately 45 min.

Data Collection and Analyses {#Sec6}
----------------------------

Questionnaire data were collected via a web-based platform (with paper questionnaires provided upon request) through YouGov.com, a third-party research and consulting services agency, and exported to a central database for analysis. Paper questionnaire responses were double-entered and merged into the database with online responses. Demographic and clinical characteristics collected at baseline in study NCT02124798 were used to characterize the sample. Data from the questionnaire were analyzed using descriptive statistics (*n*, mean, standard deviation \[SD\], and/or frequency). Planned exploratory subgroup analyses included duration of belimumab treatment, change in general symptoms, flare frequency, flare severity, and fatigue. Post hoc exploratory subgroup analyses included improvement in ability to work and preferred mode of administration.

Audio recordings of the telephone interviews were transcribed and patient identifiable information was removed prior to analysis. Personnel experienced in qualitative analysis methods analyzed the data using a study-specific coding dictionary and content analysis approach. ATLAS.ti 7.1.8. software (Scientific Software Development GmbH, Berlin, Germany) was used to create and organize concepts identified during the interviews to evaluate the underlying structure of the qualitative data. Table 1 in the ESM shows the reported frequency of the codes that support the data presented in this manuscript and provides sample quotes to support the most highly endorsed codes.Table 1Patient demographics and clinical characteristicsCharacteristicQuestionnaire (*N* = 43)^a^Qualitative interviews (*N* = 21)Age, years46.2 ± 12.247.6 ± 12.6Sex Male5 (11.6)2 (9.5) Female38 (88.4)19 (90.5)Race White32 (74.4)11 (52.4) Black or African American9 (20.9)9 (42.9) Asian2 (4.7)1 (4.8)Employment status^b^ Employed full time16 (39)6 (29) Employed part time5 (12)2 (10) Homemaker3 (7)1 (5) Unemployed1 (2)1 (5) Retired4 (10)4 (19) Disabled11 (27)6 (29) Other, self-employed1 (2)0Time since SLE diagnosis, years \<11 (2)0 2--512 (29)5 (24) 5--1010 (24)5 (24) 10--155 (12)4 (19) 15--205 (12)3 (14) \>206 (15)4 (19)Duration of belimumab use^c^ \<6 months2 (5)1 (5) 6 months--1 year10 (24)3 (14) \>1 year30 (71)19 (91)Data are presented as mean ± standard deviation or *n* (%)*SD* standard deviation, *SLE* system lupus erythematosus^a^One patient was excluded from primary analyses due to completing the survey outside of the required time frame; data for this patient were only included in exploratory analyses^b^ *n* = 41 for the questionnaire^c^ *n* = 42 for the questionnaire; first-year data blinded to patients who participated in study BEL112341

Results {#Sec7}
=======

Patient Disposition {#Sec8}
-------------------

A subset of the parent study sites was invited to join this study. In total, 95 patients participated in the parent study and 44 were invited to join this study. With one exception, all eligible patients agreed to take part in the questionnaire (*n* = 43; Fig. [1](#Fig1){ref-type="fig"}); however, one patient completed the survey outside of the required timeframe so was excluded from the primary analysis. The majority (*n* = 41) of patients switched directly from intravenous belimumab to the autoinjector; of these, one had previous experience of the subcutaneous belimumab prefilled syringe. Two patients switched directly from subcutaneous belimumab prefilled syringe to the autoinjector.Fig. 1Patient disposition. ^a^One patient was enrolled and randomized, but did not initiate treatment; ^b^one patient completed the survey outside of the required time frame so was excluded from the primary analysis; ^c^one patient had previous experience of belimumab*SC*, prefilled syringe. *IV* intravenous, *SC* subcutaneous

Patient characteristics were representative of those who completed study NCT02124798 (Table [1](#Tab1){ref-type="table"}) \[[@CR5]\]. All patients who participated in the survey completed the eight weekly autoinjector doses (Fig. [1](#Fig1){ref-type="fig"}). The majority of patients (*n* = 30 \[71%\]) had received belimumab for \>1 year.

Patient Experience with Using the Autoinjector {#Sec9}
----------------------------------------------

According to the questionnaire data, all patients were satisfied (*n* = 5 \[12%\]) or very satisfied (*n* = 37 \[88%\]) with the training they received before using the autoinjector. Patients felt confident in their ability to use the autoinjector correctly the first time they used it on their own outside of the clinic (Fig. [2](#Fig2){ref-type="fig"}). At the end of the study, 35 (83%) patients were extremely confident they could use the autoinjector correctly. During qualitative interviews, patients stated that their confidence was due to receiving adequate training. One patient recalled:Fig. 2Patient confidence in using the autoinjector alone, outside of the clinic (questionnaire results), *N* = 42 ""I was pretty confident ... actually very confident ... like I said, it's not hard to use. And with all the---the training they showed me, and being able to do it in front of them before I was able to do it on my own helped ... with my comfort level. So once I did it at home, I was just ready to do it.""

The questionnaire data showed that all patients were satisfied with using the autoinjector (*n* = 29 \[69%\] very satisfied; *n* = 11 \[26%\] satisfied; *n* = 2 \[5%\] somewhat satisfied). Qualitative interview responses (*n* = 21) showed that 17 (81%) patients reported positive experiences using the autoinjector and five (24%) patients reported having a negative experience (*n* = 2 \[10%\] patients reported both positive and negative experiences). In the qualitative interviews, the most commonly reported advantages of the autoinjector were convenience (*n* = 15 \[71%\]), easy/quick administration (*n* = 12 \[57%\]), and self-administration (*n* = 5 \[24%\]). During the qualitative interviews, all patients considered the autoinjector to be convenient, citing shorter administration time compared with their previous treatment (*n* = 8 \[38%\]), ease of administration (*n* = 5 \[24%\]), ease of incorporation into their daily routine (*n* = 4 \[19%\]), and the ability to administer at home (*n* = 4 \[19%\]) as the main advantages. One patient stated,""The convenience of just being able to go to the refrigerator, take it out, take a shower, get ready, come back out, give it to myself and be done with it. And not have to worry about missing work to do it, I can just do it in the morning as part of my routine and just do it and be done with it, that's the best part.""

Furthermore, when specifically asked about ease of use, the majority of patients (*n* = 19 \[91%\]) reported that overall the autoinjector was easy to use. For example, one patient stated, "it was just super simple and so convenient for my daily life, that was my favorite things about it".

When asked about the disadvantages of the autoinjector, 8 of 21 (38%) patients reported none and 13 (62%) patients reported some, the most common of which was injection discomfort (*n* = 5/13 \[38%\]). These patients described pain, stinging, nausea, and a lack of control of injection speed. For example, "there wasn't much that I didn't like about it, except for that it stung. It was quick, it wasn't like intolerable, I could tolerate it, it didn't make me cry or it wasn't so much that it hurt, but it did sting".

In discussing their experience of nausea, one patient stated, "I had nausea ... for many days after, that was my only ... noticeable difference between the infusion and the injection".

Pain ratings for the autoinjector were low; on an 11-point numeric rating scale (from 0 \[no pain\] to 10 \[extreme discomfort\]), 35 (83%) patients rated their discomfort as 0--3 (representing minimal pain), while three (7%) patients indicated ratings of 4--6 (representing moderate pain), and four (10%) patients indicated ratings of 7--8 (representing severe pain). Other cited disadvantages of the autoinjector included inconvenience (having to store the medication in a refrigerator and wait 30 min for it to reach room temperature before administration), not receiving enough medication, and it not being ergonomic (*n* = 2/13 for each \[15%\]). Of the two patients who thought they did not receive enough medication, one stated the dose was not sufficient for their weight and another stated, "medicine needed to be a little stronger".

Comparison of Routes of Administration of Belimumab {#Sec10}
---------------------------------------------------

A total of 32 (76%) patients who switched from intravenous belimumab to autoinjector expressed in the questionnaire a preference for the autoinjector compared with intravenous administration. During subsequent telephone interviews, patients reported that convenience, time saved (including reduced travel time, quick administration compared with time taken for intravenous administration), cost, and reduced injection pain contributed to autoinjector preference.

Considering their prior experience with intravenous belimumab, one patient recalled,""I mean, sometimes I'd feel that IV ... pull and stuff. And the site where the IV was is tender. And with that and with me being a hard person to get a vein on, sometimes I'm poked two or three times before the IV is even started.""

One patient described adverse events with intravenous belimumab, "It---when I first went on the IV ... I started soon as I ... it started going in my system I would ... the itch---I would feel itchy like on my ... my face, my back, my stomach".

Patients who preferred intravenous administration perceived that, compared with the autoinjector, intravenous belimumab more adequately controlled their symptoms. One patient suggested,""Well, right at this minute I prefer the IV, just because it makes me feel better. If they could get the autoinjector to where, you know, it makes you feel as good continuously like the IV did, then of course I would go with the autoinjector because of the convenience. But for---as of right this minute, I like the IV.""

The questionnaire results indicate that overall satisfaction, satisfaction with frequency of administration, and satisfaction with time taken to receive belimumab were higher for the autoinjector than for intravenous administration (Table [2](#Tab2){ref-type="table"}). The autoinjector was also reported to be more convenient than intravenous administration (Table [2](#Tab2){ref-type="table"}). During the qualitative interviews, satisfaction was attributed to reduced time for autoinjector administration, less travel time and interference with work, autoinjector portability, and less/no pain associated with autoinjector use. All patients stated that the autoinjector was easier to use than receiving an intravenous infusion. Seven (33%) patients indicated that it was easier to incorporate the autoinjector into their daily routine.Table 2Comparison of intravenous (*N* = 41) and autoinjector administration (*N* = 42) of belimumab, questionnaire results, and supporting quotes from the qualitative interviewsQuestionnaire sectionQuestionnaire scaleIllustrative quoteOverall satisfactionVery dissatisfiedDissatisfiedSomewhat dissatisfiedNeither satisfied nor dissatisfiedSomewhat satisfiedSatisfiedVery satisfiedIntravenous administration (*N* = 41)1 (2)1 (2)5 (12)2 (5)10 (24)17 (40)6 (14)"It's not that I was really unsatisfied with it. It's just inconvenient for me"Autoinjector administration (*N* = 42)00002 (5)11 (26)29 (69)"Um, the autoinjector is wonderful ..."Satisfaction with frequency of administration Intravenous administration (*N* = 41)2 (15)06 (14)5 (12)8 (19)14 (33)6 (14)"I just think the real positive thing for me is it's something I go get it done once a month and I don't have to deal with it on a day-to-day basis" Autoinjector administration (*N* = 42)0001 (2)019 (45)22 (52)"I didn't mind giving myself an injection once a week"Satisfaction with time taken to receive belimumab Intravenous administration (*N* = 41)1 (2)3 (7)7 (17)10 (24)10 (24)5 (12)5 (12)"I mean, you've got to sit there and wait after the thing is in your arm for an hour. Then you've got to sit, and wait, and make sure you don't have an immediate reaction before they let you go. So, right there it's an hour and a half" Autoinjector administration (*N* = 42)0002 (5)2 (5)10 (24)30 (71)"Just the convenience of it. Like it was right there. I could just wake up, leave it out for 30 minutes while I'm getting ready for work or whatever. And then, as soon as it's ready, then I can just do it and go"Questionnaire sectionQuestionnaire scaleIllustrative quoteConvenience of useNot at all convenientA little convenientModerately convenientVery convenientExtremely convenientIntravenous administration (*N* = 41)12 (29)9 (21)12 (29)5 (12)3 (7)"Not having to worry about whether I forgot to take my pills for the day or not. I know I go and I'm good for the month"Autoinjector administration (*N* = 42)00010 (24)32 (76)"Well, that it's already pre-dosed and that everything is just---that it's just completely ready, all you have to do when it gets to room temperature and, you know, for 30 minutes and then inject it, so that convenience is ideal. And that there's nothing to---I mean there's nothing that you can hurt---harm yourself with afterwards because the needle is completely encased in the device after the injection"Data are presented as *n* (%)

Patient-reported symptom changes varied when comparing the autoinjector and intravenous administration. Questionnaire results revealed that 17 (40%) patients thought their symptoms were much or somewhat better, 14 (33%) reported no change, and nine (21%) reported they were much or somewhat worse with the autoinjector than with intravenous administration. During the qualitative interviews, 11 (52%) patients reported no change in their symptom severity when using the autoinjector compared with intravenous administration; all five (24%) of the patients who reported a decrease in symptom severity attributed this to greater symptom control because of consistency provided by weekly autoinjector administration compared with monthly intravenous infusions. For example, one patient commented,""I feel like sometimes with the IV that the 4 weeks is a long time because like I said, before I go back with the, um, before the IV I have like my symptoms aren't very good---the lesions, the achiness, swelling. But with this auto I didn't have that.""

Four (19%) patients reported experiencing less severe symptoms when using intravenous administration than when using the autoinjector.

Questionnaire responses revealed low levels of discomfort (on a scale of 0 \[no discomfort\]--10 \[extreme discomfort\]) for both autoinjector (mean \[SD\] 1.8 \[2.2\]) and intravenous administrations (mean \[SD\] 1.8 \[1.9\]). Of the three patients with experience of using the prefilled syringe, one reported that discomfort was greater with the autoinjector than with the prefilled syringe. During the qualitative interviews, 17 (81%) patients reported that the discomfort of using the autoinjector was the same as that experienced with intravenous infusions; two (10%) reported greater discomfort and two (10%) reported less discomfort than with intravenous administration. Overall, according to the questionnaire, pain ratings for both autoinjector and intravenous administration routes were low and comparable, with 35 (83%) and 33 (80%) patients rating their pain as minimal, respectively.

Questionnaire data indicated that 17 (41%) patients thought autoinjector use improved their ability to carry out daily activities compared with intravenous administration; 18 (44%) patients reported no change, and four (10%) reported a decreased ability (data missing for *n* = 2 \[5%\] patients). For example, one patient stated:""It's easier for me to do things, so I do more things ... I can do more varied things because I can walk for a longer period of time ... I can drive for longer periods of time, so it's made it easier to do more. So, it's made me happier which makes everyone else happier.""

Among employed patients (*n* = 29/42 \[69%\]), use of the autoinjector was reported to have a positive impact on their ability to work (*n* = 17 \[59%\]) compared with intravenous administration; eight (28%) patients reported no change and four (14%) reported worsening of ability to work. Exploratory analyses investigated the relationship between ability to work and preference for route of administration; however, it is important to note that the subgroups for these analyses were small. Among employed patients who reported a preference for the autoinjector (*n* = 22/29 \[76%\]), *n* = 16/22 (73%) reported an improvement in their ability to work while using the autoinjector; the remaining patients in this subgroup reported no change. By comparison, only one (14%) patient who reported a preference for intravenous belimumab reported an improvement in ability to work; over half of the patients who preferred intravenous belimumab compared with the autoinjector (*n* = 4/7 \[57%\]) reported that their ability to work had worsened with intravenous treatment.

General Experience and Impact of Belimumab {#Sec11}
------------------------------------------

Patients were asked about their experience with belimumab since initiating treatment, regardless of the route of administration. A high level of satisfaction was reported for belimumab: questionnaire data revealed that 21 (50%) patients were very satisfied, ten (24%) were satisfied, and six (14%) were somewhat satisfied with their treatment; one (2%) was neither satisfied nor dissatisfied, none were dissatisfied, and two (5%) were very dissatisfied. All patients stated they would have preferred to have initiated belimumab at an earlier stage of their disease, and all patients wanted to continue receiving belimumab. In the questionnaire, the majority of patients reported improvements in overall symptoms, flare frequency and severity, and fatigue with belimumab treatment in general (Table [3](#Tab3){ref-type="table"}). Exploratory analyses showed that symptoms were more frequently reported as 'much improved' by patients who had received belimumab for \>1 year (*n* = 18/30 \[60%\]) than by those who had received belimumab for \<1 year (*n* = 3/13 \[23%\]). Similarly, results showed 'much improvement' in flare frequency (*n* = 16/30 \[53%\] vs. 2/13 \[15%\] patients), flare severity (*n* = 17/30 \[57%\] vs. 3/13 \[23%\]), and fatigue (*n* = 10/30 \[33%\] vs. 1/13 \[8%\]) in patients receiving belimumab for \>1 year compared with those receiving belimumab for \<1 year. Similar analyses suggested that patients who reported improvements in flare severity or flare frequency were more satisfied with belimumab treatment.Table 3Change in symptoms since beginning treatment with belimumab (questionnaire data; *N* = 42) and example quotes from the qualitative interviewsQuestionnaire sectionQuestionnaire scaleIllustrative quoteOverallMuch worseSomewhat worseNo changeSomewhat betterMuch better0 (0)0 (0)1 (2)20 (48)21 (50)\"I haven't had any, you know, major flares since I've been on Benlysta \[belimumab\]\"Questionnaire sectionQuestionnaire scaleIllustrative quoteFlare frequencyMuch more frequentSomewhat more frequentNo changeSomewhat less frequentMuch less frequent0 (0)1 (2)6 (14)17 (40)18 (43)\"Actually it's been quite a while now since I've had any and I was getting them fairly frequently like every few months and now it's been a few months with nothing. It's been maybe about 6 months with just, with nothing. I've been good\"Questionnaire sectionQuestionnaire scaleIllustrative quoteFlare severityMuch more severeSomewhat more severeNo changeSomewhat less severeMuch less severe0 (0)1 (2)5 (12)16 (38)20 (48)\"Well after I started Benlysta \[belimumab\], it took a minute for it to kick in. But I noticed the flare wasn't as bad and the pain wasn't as bad after I started Benlysta \[belimumab\]\"Questionnaire sectionQuestionnaire scaleIllustrative quoteFatigueMuch more severeSomewhat more severeNo changeSomewhat less severeMuch less severe2 (5)0 (0)8 (19)21 (50)11 (26)\"Before I would have to sleep 12 to 14 hours a night and I would still wake up exhausted, that's not the case anymore. I can sleep 8 to 10 hours and honestly it's usually 10 hours a night, so more rested. However, I don't remember a day of ever not feeling fatigued at all, so it's definitely improved\"Data are presented as *n* (%)

During the qualitative interviews, the most commonly cited advantages of belimumab were improvements in symptoms/flares (*n* = 10 \[48%\]), that it was more effective than other treatments (*n* = 5 \[24%\]), and that it improved HRQoL (*n* = 5 \[24%\]). The majority of patients (*n* = 17 \[81%\]) said there were no disadvantages to belimumab; however, three (14%) thought it did not sufficiently alleviate symptoms and two (10%) stated that cost was a disadvantage. For example, one patient said, "The only disadvantage that I have about it is, you know, it's---you know, with any other medication, the cost, that's the only thing, you know, is just the cost of it".

Questionnaire results also indicated improvements in HRQoL since initiation of belimumab, including ability to work (attendance/performance; *n* = 15 \[36%\]), personal relationships (*n* = 22 \[52%\]), leisure activities (*n* = 20 \[48%\]), and activities of daily living such as grooming, bathing and running errands (*n* = 29 \[69%\]). Eight (19%) patients experienced no improvements in HRQoL following initiation of belimumab. Of the 30 patients receiving concomitant steroids, 20 (67%) had reduced their steroid use since initiating belimumab treatment.

Discussion {#Sec12}
==========

This study provides evidence regarding general satisfaction and preferences of patients with SLE for belimumab treatment and autoinjector administration. The online/paper questionnaire and qualitative interview data demonstrate that patients with SLE who used the autoinjector to self-administer belimumab in a trial designed to reflect real-world use found the autoinjector easy to use, viewed belimumab as effective for the treatment of SLE symptoms, and expressed a preference to continue belimumab treatment if it was made available to them. Furthermore, 76% of patients expressed a preference for the autoinjector over intravenous administration for a variety of reasons, including convenience, time saved, cost, and reduced injection pain.

Patients were positive regarding their SLE symptom and HRQoL experiences when adding belimumab to SoC. Many patients reported that subcutaneous belimumab improved their ability to work and carry out daily activities. The positive experiences of patients reported here support the outcome of a physician and patient satisfaction survey of intravenous belimumab, in which good overall patient satisfaction with belimumab was demonstrated \[[@CR2]\]. This study demonstrates that switching to autoinjector administration of belimumab also led to positive feedback in these areas. Furthermore, patients commonly reported satisfaction with the device, ease of use, convenience, and confidence with administration. Use of autoinjector devices has previously been shown as a strong predictor of drug adherence in patients with multiple sclerosis \[[@CR11]\]. Improved patient satisfaction with subcutaneous belimumab administered via autoinjector may translate into improved adherence and consequential response to treatment.

Data from the present study regarding autoinjector ergonomics are consistent with those reported by healthy volunteers who found the device comfortable to hold \[[@CR4]\]. Pain levels were low in the healthy volunteer study and in this study \[[@CR4]\]. By comparison, injection discomfort was stated as a disadvantage in the present study by approximately one-quarter of patients. A small number of qualitative interview patients reported other disadvantages, including inconvenience, not receiving enough medication, and poor autoinjector ergonomics. Although one patient in this 8-week study thought the dose was insufficient due to their weight, data from the 52-week BLISS-SC trial demonstrated that the efficacy of subcutaneous belimumab was maintained across weight quartiles \[[@CR6]\].

Patients expressed overall satisfaction with both the autoinjector and intravenous administration. Although patients did report some disadvantages, the majority indicated they generally preferred the autoinjector, with ease of administration, administration time, ease of incorporation into their daily routine, and ability to administer at home cited as key reasons. This is consistent with studies in patients with rheumatoid arthritis, which have also reported favorable patient evaluation of autoinjector devices \[[@CR12]--[@CR14]\].

Symptom improvements when using the autoinjector compared with intravenous administration were reported by 40% of patients in the questionnaire; telephone interviews revealed that symptom frequency was either consistent or improved in all patients who switched from intravenous administration to the autoinjector and that 24% of patients experienced a decrease in symptom severity. Treatment frequency was considered by some patients to be a further advantage; patients who reported a decrease in symptom severity with the belimumab autoinjector attributed this to improved symptom control consistency associated with weekly dosing.

Reported limitations of study NCT02124798 also affect this study \[[@CR5]\]. Results from this study should also take into account limitations associated with self-selection bias, recall bias, unblinding, and concomitant medication use. Additionally, the majority of patients in the study population had been receiving belimumab for at least 1 year, so the experiences of patients with \<1 year of treatment may not be adequately captured. The number of patients who switched from prefilled syringe to autoinjector device was low; therefore, no comparisons can be made between these modes of administration. However, a systematic review found that, in the majority of studies assessing patient preference for routes of treatment administration (including a study in patients with rheumatoid arthritis), patients preferred using an autoinjector device over a prefilled syringe, and the autoinjector device was associated with less injection site pain \[[@CR3]\]. The overall sample size was adequate to achieve concept saturation (the point at which no new information is obtained from subsequent interviews); in qualitative studies with straightforward concepts, saturation is generally reached with a sample of 18--20 patients. However, the number of patients in the exploratory analyses subgroups was low, therefore, these results should be interpreted with caution.

The availability of the autoinjector for self-administration of subcutaneous belimumab provides an additional treatment option for patients with SLE, and results from this study clearly signal the potential benefits of belimumab and autoinjector use in SLE. The favorable opinion expressed by patients in this study reinforces the clinical improvements and HRQoL impacts of intravenous belimumab demonstrated in previous studies \[[@CR7], [@CR8], [@CR15]\], and suggests that patient outcomes may be improved by the use of the autoinjector.

Conclusions {#Sec13}
===========

Participants indicated a high level of satisfaction with the autoinjector. Results from this study suggest that patients would prefer to continue using belimumab treatment for SLE and that, compared with intravenous belimumab, the autoinjector has clear patient benefits and was the preferred administration route for three-quarters of patients. Further longitudinal studies will be conducted to confirm the findings of this cross-sectional study, to assess change in patient outcomes over time, and to evaluate the long-term use of the autoinjector device for the administration of belimumab to treat SLE.
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